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Background: Identifying allergic rhinitis requires allergy testing, but the first-line referral for rhinitis are usually
primary care physicians (PCP), who are not familiar with such tests. The availability of easy and simple tests to be
used by PCP to suggest allergy should be very useful.
Methods: The Respiratory Allergy Prediction (RAP) test, based on 9 questions and previously validated by a panel
of experts, was evaluated in this study.
Results: An overall number of 401 patients (48.6% males, age range 14–62 years) with respiratory symptoms was
included. Of them, 89 (22.2%) showed negative results to SPT, while 312 (77.8%) had at least one positive result to
SPT. Cohen’s kappa coefficient showed that all questions had an almost perfect excellent agreement between pre
and post-test. The algorithm of decision-tree growth Chi-squared Automatic Interaction Detector showed that
answering yes to the question 4 (Your nasal/ocular complains do usually start or worsen during the spring?),
6 (Did you ever had cough or shortness of breath, even during exercise?) and 8 (Do you use nasal sprays
frequently?) gave a probability to have a positive SPT of 85%.
Conclusions: These findings show that RAP test can be proposed as an useful tool to be used by physician other
than allergists when evaluating patients with rhinitis, suggesting the need of allergy testing.
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Allergic rhinitis (AR) is the most frequent immune-
mediated disorder, and its prevalence is still increasing
worldwide, as recently underlined in the Gene Environ-
ment Interactions in Respiratory Diseases (GEIRD) epi-
demiological study [1]. AR is defined as a symptomatic
disorder of the nasal mucosa, due to an IgE-mediated re-
action that follows the immediate contact with an
offending allergen. The major symptoms of AR are nasal
itching, sneezing, rhinorrhea and obstruction, that are
spontaneously reversible or may be controlled by ad-
equate treatment [2]. AR may also be part of the Severe
Chronic Upper Airways Disease (SCUAD) [3] and is fre-
quently associated with comorbidities such as rhinosinu-
sitis, asthma, conjunctivitis, nasal polyposis, and sleep* Correspondence: ffrati@stallergenes.it
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unless otherwise stated.disturbances, which make the diagnostic approach more
complex [4]. Nevertheless, AR is still often considered as
a “trivial” disease, that can be easily manageable by the
patient himself or by healthcare providers other than
physicians. Instead, its health and social impact is sub-
stantial, considering the costs, either direct (expenditure
for drugs, access to medical care) or indirect (absentee-
ism, presenteism, decreased school/work performance)
[5-7]. Finally, AR is frequently associated with asthma
but, more importantly, it represents the more relevant
independent risk factor for asthma onset [8]. In this com-
plex context, primary care physicians and also pharmacists
are usually the first-line referral for AR patients, but thus
far there is no easy, simple and self-administered test to be
used in the primary care physician setting to discriminate
a suspicion of AR, so that the patient can be subsequently
referred to the allergist for a more detailed or confirma-
tory diagnosis by skin prick test (SPT), in vitro IgE assay,
specific provocation test or molecular-based diagnosis.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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questionnaire, to be used in primary care, able to identify
with a good positive predictive value the presence of AR.
Methods
An initial version of the questionnaire, named Respira-
tory Allergy Prediction (RAP) test, involving 10 yes/no
questions was agreed by a panel of experts, based on lit-
erature data, personal experience and clinical observa-
tions. This first version was then used in a pilot study
including 40 patients (approved by the Ethic Committee
of the Ospedale Maggiore della Carità, Novara, Italy, N.
CE 45/08) [9]. The questionnaire underwent a pre- and
re-test procedure, followed by the standard diagnostic
work-up for allergy diagnosis. The preliminary evalu-
ation allowed to obtain a final version of the RAP ques-
tionnaire in 9 questions, as reported in Table 1, that was
evaluated and validated in a large sample of patients,
object of the present observational, multicenter, pro-
spective study. The results of the RAP test (including
test-retest analysis) were compared to the results of
SPTs, obtained in a blinded fashion.
The primary objective was to set-up a simple clinical
questionnaire in Italian language for the primary care
physicians able to suggest AR with a good positive pre-
dictive value.
The primary efficacy variables were:
– Validity, the capacity of the questionnaire to
recognize AR compared with an evaluation by SPT,
performed in blinded fashion by the physician
during the visit;
– Reliability. The reliability of the questionnaire, i.e.
the capacity to provide stable measurements in the
case of the stability of environment, was assessed by
repeating the administration of the questionnaire on
all included patients.
The secondary objectives were the evaluation of the
predictivity of each question concerning respiratoryTable 1 The 9-question RAP questionnaire
1 Do you have parents/relatives suffering from rhinitis and/or asthma?
2 Do you suffer from itchy/red/watery eyes during the year?
3 Do you experience runny nose/nasal obstruction/nasal itching
for many consecutive days?
4 Your nasal/ocular complaints do usually start or worsen during the spring?
5 Have you ever heard wheezing breath?
6 Did you ever had cough or shortness of breath, even during exercise?
7 Do you have nocturnal awakenings due to shortness of breath or cough?
8 Do you use nasal sprays frequently?
9 Do you feel that your nasal symptoms worsen in dusty environments?
Y/N answers allowed.allergy and characterization of allergic condition in the
studied sample.
All the assessments in the study were in blinded con-
dition and the data were registered in case report form.
Patients
The patients were enrolled consecutively among those
referred for the first time because of a suspected AR, as
suggested by symptoms such as rhinorrhea, itching,
sneezing, and nasal obstruction, with or without lower
respiratory symptoms, to 9 Allergy Units distributed
over the Italian territory. The Units were: Allergy and
Clinical Immunology Unit, Ospedale Maggiore della
Carità, Novara; Pediatric Unit, Riuniti Hospital, Tortona;
Allergy Unit, Riuniti Hospital, Rivoli; Pediatric Unit,
Riuniti Hospital, Rivoli; Allergy Unit, Carlo Poma
Hospital, Mantova; Allergy and Clinical Immunology
Unit, G. Martino Hospital, Messina; Immunohaematol-
ogy and Transfusion Service, Azienda Sanitaria Unica
Regionale Zona 13, Ascoli Piceno; Department of Clin-
ical Medicine and Immunological Sciences, Santa Maria
alle Scotte Hospital, Siena; Allergy Service/Pneumology
Unit, Cervello Hospital, Palermo.
Inclusion criteria were: patients reporting respiratory
symptoms; age between 6 and 60 years; written informed
consent to participate to the study; patients already eli-
gible for SPT.
Exclusion criteria were: a previous physician-based
diagnosis of AR and/or stably treated with symptomatic
medications (e.g. antihistamines, nasal corticosteroids,
nasal decongestants) or allergen immunotherapy, occur-
rence of skin disorders such as atopic dermatitis, dermo-
graphism or other pathologies potentially interfering
with skin reactivity; patients with psychiatric disorders.
The patients had to fill the RAP questionnaire two
times (test-retest) before undergoing the diagnostic pro-
cedures by SPTs.
Table 1 shows the 9 items of the questionnaire.
SPTs were performed in all centres with the same
panel of commercial extracts (Stallergenes Italy, Milan),
including dust mites, grasses, Parietaria, birch, hazelnut,
olive, cypress, mugwort, ragweed, cat/dog epithelia, and
cockroach, that represent the most common sensitizers
in Italy. Positive (histamine) and negative (diluent) con-
trols were also used, and the results were read after
20 minutes according to European guidelines [10].
Ethical aspects
Written informed consent was obtained by each partici-
pant before entering the study, and in the case of minors
was obtained from next of kin, caregivers, or guardians.
The study was conducted in accordance with good clin-
ical practice guidelines. The ethics committees at each
of the participating sites approved the study.
Table 2 Main demographic and clinical characteristics of
the 401 patients
N %
Male/female 195/206 48.6/51.4
Mean age (range) 26.1 (14–62)
Smoking habit
Current 56 14
Never/former 343 86
Allergic rhinitis yes/no 365/36 91/9
Allergic rhinitis classification
Mild intermittent 107 29.3
Mild persistent 80 21.9
Moderate/severe intermittent 55 15.1
Moderate/severe persistent 123 33.7
Asthma yes/no 143/258 35.7/64.3
Asthma classification
Intermittent 84 58.7
Mild persistent 34 23.8
Moderate persistent 24 16.8
Severe persistent 1 0.7
Conjunctivitis yes/no 238/163 59.4/40.6
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A heuristic sample size of about 450 patients was hy-
pothesized as sufficient to evaluate the efficacy of the
questionnaire. To interpret the efficiency of the ques-
tionnaire in predicting allergy, we used the algorithm of
decision-tree growth Chi-squared Automatic Interaction
Detector (CHAID), a method that automatically searches
for important patterns and relationships and quickly un-
covers hidden structure even in highly complex data. In
other words, subdivisions of the tree are constructed so
as to maximize the differences in response between the
two groups of the split [11].
The variable “target” used is the SPT, classified in two
categories of positivity: YES and NO. The explanatory
variables are represented instead by a questionnaire with
9 questions administered to patients during the examin-
ation. The reliability of agreement between pre and
post-test were analyzed by Cohen’s kappa coefficient.
The measure calculates the degree of agreement in clas-
sification over that which would be expected by chance.
Landis and Koch [12] gave the following values for
interpreting k values:
– 0.01 to 0.20, slight agreement;
– 0.21 to 0.40, fair agreement;
– 0.41 to 0.60, moderate agreement;
– 0.61 to 0.80, substantial agreement and almost
perfect from
– 0.81 to 1 almost perfect agreement.
Data were also plotted in Receiving Operating Curve
(ROC), in which area under the curve (AUC) corre-
sponds to a likelihood that a positive response is more
frequent than a negative response. An ideal model pro-
vides an AUC as 1; a random model, in which a positive
response to the presence of a symptom is not correlated
with the positivity to SPT, provides an AUC as 0.5.
Results
A total of 426 patients were enrolled and included in the
database. Of them, 25 patients erroneously received a ver-
sion of the questionnaire and were therefore excluded, re-
ducing to 401 (48.6% males, mean age 26.1 years, age
range 14–62 years) the number of patients analyzed.
Patients were referred to the specialists by primary
care physicians in 292/401 (72.8%), pediatricians in 39/
401 (9.7%), Ear Nose Throat (ENT) specialists in 28/401
(7%), pulmonologists in 14/401 (3.5%) and ophtalmolo-
gists in 6/401 (1.5%).
Their main demographic and clinical characteristics
are reported in Table 2. The sample was mainly com-
posed by non-smokers (297/401, 74.5%). Table 3 shows
the differences according to smoking habit, that were
not statistically significant.The most commonly reported symptoms were nasal
symptoms in 368/401 (91.8%), followed by ocular symp-
toms in 238/401 (59.4%) and bronchial symptoms in
205/401 (51.1%) patients.
Asthma was diagnosed by attending physician in 143/
401 (35.7%) patients. The asthma clinical stage (intermit-
tent, mild persistent, moderate persistent, severe persist-
ent) is reported in Table 2.
AR was diagnosed by attending physician in 365/401
(91%) patients. The AR clinical stage (mild intermittent,
mild persistent, moderate/severe intermittent, moderate/
severe persistent) is reported in Table 2.
Atopic dermatitis was diagnosed in 33/401 (8.2%) and
conjunctivitis in 238/401 (59.4%) patients.
Two hundred thirty nine patients (59.6%) had received
at least one symptomatic treatment in the latest 6 months.
The treatments were: anti-histamines in 152/401 (38%),
short acting β2 agonists in 45/401 (11.25%), long acting β2
agonists in 45/401 (11.2%), nasal topic steroids in 72/401
(18%), bronchial topic steroids in 69/401 (17.2%) and anti-
leukotrienes in 16/401 (4%) patients.
Three hundred twelve patients (77.8%) showed posi-
tive results to SPT, while 89 (22.2%) negative results.
Table 4 shows all the positive results to the different al-
lergens and their distribution according to the grade of
positivity from 1 + to 4 +.
The analysis by the Cohen’s kappa coefficient showed
that all questions had a almost perfect concordance be-
tween pre and post-test, with value higher than 0.81.
Table 3 Differences in severity of allergic rhinitis according to smoking habit
Observed frequencies Significance by Fisher’s exact test
Severity of AR/smoking habit Total
Current Never/former Current Never/former
Mild intermittent 10 96 96 Mild intermittent < >
Mild persistent 17 63 80 Mild persistent > <
Moderate/severe intermittent 11 43 43 Moderate/severe intermittent > <
Moderate/severe persistent 17 106 106 Moderate/severe persistent < >
Total 56 343 399
Theoretical frequencies Percentage/Column
Severity of AR/smoking habit Total
Current Never/former Current Never/former
Mild intermittent 14.877 91.123 106.000 Mild intermittent 17.857 27.988
Mild persistent 11.228 68.772 80.000 Mild persistent 30.357 18.367
Moderate/severe intermittent 7.579 46.421 54.000 Moderate/severe intermittent 19.643 12.536
Moderate/severe persistent 17 106 123.000 Moderate/severe persistent 30.357 30.394
Total 56 343 399 Total 100 100
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to each question and the result of SPTs allowed to build
a decision tree (Figure 1). Based on such correlation the
most important questions selected by decision-tree
growth CHAID were Q4, Q8, Q6 and Q1.
Answering yes to the question 4, 6 and 8 gave a prob-
ability to have a positive SPT of 85%. Answering yes to
Q4, Q6 and Q8 and no to Q1 gave a probability to have
a positive SPT of 94.6%. The solidity of the used model
was demonstrated by an AUC value corresponding to
0.675, defining a correct classification of the positive an-
swers of around 80%. Thus, the final RAP questionnaire,Table 4 Positive results to skin prick tests
Allergen Positive result (%)
Dermatophagoides pteronyssinus 146(36.4%)
Dermatophagoides farinae 142(35.5%)
Grass pollen 174(43.6%)
Olive pollen 93(24.2%)
Cat epithelium 82(21.6%)
Parietaria pollen 78(19.5%)
Ragweed 69(17.6%)
Mugwort 56(14.5%)
Tree pollen (birch, hazelnut, 51(13%)
Cypress pollen 49(13.6%)
Dog epithelium 48(13%)
Alternaria 40(10.3%)
Cockroach 1(0.7%)to be proposed for clinical use, is composed of 4 ques-
tions as reported in Table 5.
Discussion
AR is a high prevalence disease. Its impact on the quality
of life, also due to the numerous comorbidities (including
asthma, sleep disturbances, otitis, rhinosinusitis) is recog-
nized on scientific bases [13-15] and is well known to al-
lergy specialists. However, the general perception of AR is
that of a mild disease, because it is not life-threatening,
and its economic burden is generally underestimated. In-
deed, recent data showed that patients perception isGrading of positive results
1 + (%) 2 + (%) 3 + (%) 4 + (%)
22(15.1%) 36(24.7%) 50(34.2%) 38(26%)
23(16.2%) 43(30.3%) 41(28.9%) 35(24.6%)
17(9.8%) 47(27%) 59(33.9%) 51(29.3%)
9(9.7%) 25(26.9%) 31(33.3%) 27(29%)
15(18.3%) 37(45.1%) 21(25.6%) 9(11%)
5(6.4%) 16(20.5%) 15(19.2%) 41(52.6%)
7(10.2%) 9(13%) 28(40.6%) 25(36.2%)
8(14.3%) 24(42.8%) 16(28.6%) 8(14.3%)
6(11.8%) 21(41.2%) 11(21.6%) 12(23.5%)
12(24.5%) 22(44.9%) 10(20.4%) 5(10.2%)
17(35.4%) 23(47.9%) 7(14.6%) 1(2.1%)
9(22.5%) 18(45%) 11(27.5%) 2(5%)
1(100%) 0(0%) 0(0%) 0(0%)
Figure 1 Decision-tree growth CHAID. The decision tree based on such correlation the most important questions selected by decision-tree
growth CHAID were Q4, Q8, Q6 and Q1.
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ation of symptoms, the impairment of sleep and emotional
life and the cost of the disease compared with little per-
ceived benefit [5]. Primary care physicians and also phar-
macists are the first-line referral for this problem, which is
usually underestimated and managed with over-the-
counter medications [16]. On the other hand, a correct
management can be performed only after AR is properly
diagnosed. The etiologic diagnosis of AR is based on theTable 5 The final 4-question RAP questionnaire
1 Do you have parents/relatives suffering from rhinitis and/or asthma?
4 Your nasal/ocular complaints do usually start or worsen during the spring?
6 Did you ever had cough or shortness of breath, even during exercise?
8 Do you use nasal sprays frequently?
Y/N answers allowed.correlation of history data and results of test to detect IgE-
mediated sensitization [17], but this diagnosis is rarely
done in general practice [18]. Actually, primary care physi-
cians are not familiar with SPTs with allergen extracts and
if in vitro IgE tests are requested there is the problem of
their interpretation, that often is not simple. This makes
useful the availability of easy-to-use instruments to diag-
nose or, at least, suspect AR in the primary care physician
setting. For these reasons we designed this study to set up
and validate a self-administered diagnostic questionnaire,
the respiratory allergy prediction (RAP) test, that can be
self-completed by the patient, the results of which can
prompt the physician to ask for a specialty referral. The
items of the RAP questionnaire, set up by a panel of ex-
perts and preliminary evaluated in a pilot study, addressed
the family history of rhinitis and/or asthma, the occur-
rence of nasal and ocular symptoms during the year, the
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symptoms in dusty environment, the occurrence of bron-
chial symptoms and of nocturnal awakenings caused by
them, and the frequent use of nasal sprays. The results of
SPT were used to confirm the diagnosis of AR, and the
statistical analysis assessed the probability of answering
yes to the questions to be followed by positive SPT. SPT
was chosen because it is suggested in the consensus docu-
ment Allergic Rhinitis and its Impact on Asthma (ARIA)
as the first-line test [2]. The present study shows that the
RAP test allows to suspect AR with an high probability
to obtain confirmation by positive SPT. In particular,
answering yes to the question 4 (“Your nasal/ocular
complaints do usually start or worsen during the
spring?”) gave a probability of AR of 85.4%. Indeed, the
strong power of the question concerning the seasonality
of symptoms highlights an actual difference between
AR and non AR. In fact, most non AR are perennial,
while the occurrence of symptoms during the spring is
strictly related to allergic sensitization to pollens. Thus,
answering no to question 4 draws the attention on non
AR and makes useful further investigations, such as
nasal cytology, that enables to identify clinical forms as
eosinophilic non-allergic rhinitis (NARES), non-allergic
rhinitis with mast cells (NARMA), neutrophilic non-
allergic rhinitis (NARNA), and eosinophil-mast cell
non-allergic rhinitis (NARESMA) [19]. Based on the
number of questions, many combinations of responses
(as shown in the Figure 1 on the decision tree) were
generated. The highest probability (94.6%) to have posi-
tive results to SPTs was associated to the combination
of answering yes to Q4, Q6 and Q8 and no to Q1. This
may appear surprising considering that Q1 concerns the
positive family history for rhinitis and/or asthma, but
such finding is simply statistical. For the purpose of the
RAP, the probability of 85% given by the combination of
answering yes to Q4, Q6 and Q8 meets the aim to iden-
tify patients to be evaluated by the allergist.
The strength of this study is to make available a simple
tool to be used in primary care to confirm, by its high
predictive value, the clinical suspect of respiratory al-
lergy and thus suggesting the real indication to perform
allergy testing. The limitation concerns the fact that the
allergens used for skin tests were those from a European
standard panel, including the 12 most frequently respon-
sible inhalant allergens. This makes possible that pa-
tients sensitized to more rarely responsible allergens
may not be correctly identified. Also, the age range of 14
to 62 years makes the RAP test not usable in children,
who deserve a specific study.
The prevalence of AR in the studied population of
subjects with nasal symptoms, as demonstrated by the
concordance of symptoms and positive SPT was around
70%. This value is in substantial agreement with recentepidemiological data [20,21]. The rhinitis symptoms are
unable to directly suggest the diagnosis, because they are
similar in AR and in nonallergic rhinitis, and thus many
patients (approximately 30% in our study) with nonaller-
gic rhinitis are referred to allergists to perform diagnos-
tic tests. A number of questionnaires for AR were
proposed for epidemiological investigations [22], but all
patients are generally also evaluated by allergy tests and
no data are available on the ability of the questionnaire
to identify the really allergic patients. Thus, the RAP
questionnaire is the first aimed at this goal. Currently,
the questionnaire may only apply to Italy and a valid-
ation in different countries is needed.
The use of RAP test, and of similar questionnaires to
predict allergy in patients with rhinitis symptoms, possibly
adapted to local environmental natural occurrence of in-
halant allergens, has several implications in terms of costs,
by reducing the number of subjects to be referred to aller-
gists for testing, as well as of practice, enabling primary
care physicians and pharmacists to screen subjects with
suspected AR, and of management, indicating the appro-
priate treatment, that is substantially different in allergic
and nonallergic rhinitis, especially considering disease-
modifying intervention such as allergen immunotherapy.
In conclusion, the RAP test can be proposed as an useful
tool to be used by primary care physicians and specialists
other than allergists when evaluating patients with rhinitis.
Answering yes to the questions concerning the seasonality
of symptoms, to have or have had cough and shortness of
breath and to use frequently nasal sprays gives high prob-
ability to have respiratory allergy and suggests a real need
of allergy testing. This is likely to improve the suitability of
patient referral to the allergist and thus to reduce the
number of inappropriate tests.Abbreviations
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